Endonovo Therapeutics Inc
Endonovo Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and distribution of non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical… Read more
Endonovo Therapeutics Inc (ENDV) - Net Assets
Latest net assets as of June 2025: $-27.82 Million USD
Based on the latest financial reports, Endonovo Therapeutics Inc (ENDV) has net assets worth $-27.82 Million USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($17.95K) and total liabilities ($27.84 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-27.82 Million |
| % of Total Assets | -155042.57% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 1328.72 |
Endonovo Therapeutics Inc - Net Assets Trend (2010–2024)
This chart illustrates how Endonovo Therapeutics Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Endonovo Therapeutics Inc (2010–2024)
The table below shows the annual net assets of Endonovo Therapeutics Inc from 2010 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-26.80 Million | -11.19% |
| 2023-12-31 | $-24.11 Million | +25.09% |
| 2022-12-31 | $-32.18 Million | -104.00% |
| 2021-12-31 | $-15.77 Million | -9.74% |
| 2020-12-31 | $-14.37 Million | +29.90% |
| 2019-12-31 | $-20.50 Million | -79.99% |
| 2018-12-31 | $-11.39 Million | -19.28% |
| 2017-12-31 | $-9.55 Million | -11.54% |
| 2016-12-31 | $-8.56 Million | -12.81% |
| 2015-12-31 | $-7.59 Million | -61.72% |
| 2014-12-31 | $-4.69 Million | -13.57% |
| 2013-12-31 | $-4.13 Million | -119.66% |
| 2012-12-31 | $-1.88 Million | -2714.09% |
| 2011-12-31 | $71.96K | -56.66% |
| 2010-12-31 | $166.05K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Endonovo Therapeutics Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7061128400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $54.37K | % |
| Other Components | $44.17 Million | % |
| Total Equity | $-26.80 Million | 100.00% |
Endonovo Therapeutics Inc Competitors by Market Cap
The table below lists competitors of Endonovo Therapeutics Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Seven Principles AG
XETRA:T3T1
|
$51.11K |
|
Blue Ribbon Income Fund
TO:RBN-UN
|
$51.21K |
|
Biomotion Sciences Warrant
NASDAQ:SLXNW
|
$51.22K |
|
Mango Capital Inc
PINK:MCAP
|
$51.26K |
|
LOGN3F
SA:LOGN3F
|
$51.09K |
|
Neon Equity AG
XETRA:D77
|
$51.08K |
|
CANTOURAGE GROUP SE O.N.
F:HIGH
|
$51.02K |
|
Picton Property Income Ltd
LSE:PCTN
|
$51.02K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Endonovo Therapeutics Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -24,106,371 to -26,802,806, a change of -2,696,435.
- Net loss of 2,797,297 reduced equity.
- New share issuances of 97,859 increased equity.
- Other comprehensive income increased equity by 32,541.
- Other factors decreased equity by 29,538.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.80 Million | -10.44% |
| Share Issuances | $97.86K | +0.37% |
| Other Comprehensive Income | $32.54K | +0.12% |
| Other Changes | $-29.54K | -0.11% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Endonovo Therapeutics Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2009-12-31 | $3.33 | $0.00 | x |
| 2010-12-31 | $3.66 | $0.00 | x |
| 2011-12-31 | $1.59 | $0.00 | x |
| 2012-12-31 | $-39.08 | $0.00 | x |
| 2013-12-31 | $-56.56 | $0.00 | x |
| 2014-12-31 | $-154.95 | $0.00 | x |
| 2015-12-31 | $-78.37 | $0.00 | x |
| 2016-12-31 | $-72.93 | $0.00 | x |
| 2017-12-31 | $-29.16 | $0.00 | x |
| 2018-12-31 | $-31.43 | $0.00 | x |
| 2019-12-31 | $-29.40 | $0.00 | x |
| 2020-12-31 | $-1.18 | $0.00 | x |
| 2021-12-31 | $-0.26 | $0.00 | x |
| 2022-12-31 | $-0.23 | $0.00 | x |
| 2023-12-31 | $-0.02 | $0.00 | x |
| 2024-12-31 | $-0.05 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Endonovo Therapeutics Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -27853.20%
- • Asset Turnover: 0.52x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-19.38%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2009 | -137.50% | -550.00% | 0.25x | 1.00x | $-354.00K |
| 2010 | -41.79% | -114.55% | 0.36x | 1.01x | $-86.00K |
| 2011 | -130.75% | -196.97% | 0.65x | 1.02x | $-101.28K |
| 2012 | 0.00% | -6260.59% | 0.39x | 0.00x | $-1.73 Million |
| 2013 | 0.00% | -12634.50% | 0.31x | 0.00x | $-2.48 Million |
| 2014 | 0.00% | -3966.16% | 0.53x | 0.00x | $-490.19K |
| 2015 | 0.00% | -119087.95% | 0.06x | 0.00x | $-4.32 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.46 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.86 Million |
| 2018 | 0.00% | -7729.53% | 0.02x | 0.00x | $-5.30 Million |
| 2019 | 0.00% | -5582.37% | 0.09x | 0.00x | $-15.26 Million |
| 2020 | 0.00% | -238.60% | 0.06x | 0.00x | $1.04 Million |
| 2021 | 0.00% | -4247.17% | 0.04x | 0.00x | $-1.53 Million |
| 2022 | 0.00% | -13649.17% | 0.11x | 0.00x | $-15.26 Million |
| 2023 | 0.00% | 4937.60% | 0.22x | 0.00x | $9.34 Million |
| 2024 | 0.00% | -27853.20% | 0.52x | 0.00x | $-117.02K |
Industry Comparison
This section compares Endonovo Therapeutics Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Endonovo Therapeutics Inc (ENDV) | $-27.82 Million | -137.50% | N/A | $51.10K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |